248 related articles for article (PubMed ID: 32797326)
1. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality.
Smart L; Fawkes N; Goggin P; Pennick G; Rainsford KD; Charlesworth B; Shah N
Inflammopharmacology; 2020 Oct; 28(5):1141-1152. PubMed ID: 32797326
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence?
Kutti Sridharan G; Kotagiri R; Chandiramani VH; Mohan BP; Vegunta R; Vegunta R; Rokkam VRP
Am J Ther; 2020; 27(4):e400-e402. PubMed ID: 32366740
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of targeting ACE2 in COVID-19.
Elmorsi R
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9744-9747. PubMed ID: 33015820
[TBL] [Abstract][Full Text] [Related]
4. Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection.
Micallef J; Soeiro T; Jonville-Béra AP;
Therapie; 2020; 75(4):355-362. PubMed ID: 32418728
[TBL] [Abstract][Full Text] [Related]
5. Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-κb pathways in non-pregnant and pregnant populations.
Celik O; Celik N; Aydin S; Baysal B; Aydin S; Saglam A; Gursu Y; Dalkilic S; Ulas M; Ozcil MD; Tayyar AT; Cengiz F; Ugur K; Akkoc RF; Ersahin AA
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):221-229. PubMed ID: 32538775
[TBL] [Abstract][Full Text] [Related]
6. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
[TBL] [Abstract][Full Text] [Related]
7. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.
Ni W; Yang X; Yang D; Bao J; Li R; Xiao Y; Hou C; Wang H; Liu J; Yang D; Xu Y; Cao Z; Gao Z
Crit Care; 2020 Jul; 24(1):422. PubMed ID: 32660650
[TBL] [Abstract][Full Text] [Related]
8. Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2.
Kaur U; Acharya K; Mondal R; Singh A; Saso L; Chakrabarti S; Chakrabarti SS
Eur J Pharmacol; 2020 Nov; 887():173545. PubMed ID: 32926917
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Mehta N; Mazer-Amirshahi M; Alkindi N; Pourmand A
Am J Emerg Med; 2020 Jul; 38(7):1488-1493. PubMed ID: 32336586
[TBL] [Abstract][Full Text] [Related]
10. Covid-19: the renin-angiotensin system imbalance hypothesis.
Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
Buckley LF; Cheng JWM; Desai A
J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766
[TBL] [Abstract][Full Text] [Related]
12. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells.
Stelzig KE; Canepa-Escaro F; Schiliro M; Berdnikovs S; Prakash YS; Chiarella SE
Am J Physiol Lung Cell Mol Physiol; 2020 Jun; 318(6):L1280-L1281. PubMed ID: 32432918
[TBL] [Abstract][Full Text] [Related]
13. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
[TBL] [Abstract][Full Text] [Related]
14. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
15. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists.
Steckelings UM; Sumners C
Clin Sci (Lond); 2020 Nov; 134(22):2987-3006. PubMed ID: 33210709
[TBL] [Abstract][Full Text] [Related]
16. Ibuprofen and COVID-19 disease: separating the myths from facts.
Poutoglidou F; Saitis A; Kouvelas D
Expert Rev Respir Med; 2021 Aug; 15(8):979-983. PubMed ID: 34196258
[No Abstract] [Full Text] [Related]
17. ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror.
Kelleni MT
Inflammopharmacology; 2020 Dec; 28(6):1477-1480. PubMed ID: 32920716
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
19. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
20. ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations.
Snyder EM; Johnson BD
Pharmacogenomics; 2020 Jul; 21(10):695-703. PubMed ID: 32501190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
